Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Milestone Pharmaceuticals Inc's Business Segments
Milestone Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single Reportable Segment
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Single Reportable Segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | $ 0 | 100% |
Description of Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc. is a research-driven biopharmaceutical company that focuses on developing and commercializing novel therapies for cardiovascular and metabolic diseases. The company is based in Montreal, Canada and was founded in 200
Milestone Pharmaceuticals Inc. is primarily focused on developing drugs that target cardiovascular and metabolic disorders, including hypertension, atrial fibrillation, and heart failure. The company's lead product candidate is called etripamil, which is a calcium channel blocker that is delivered through a nasal spray. Etripamil is being developed for the treatment of paroxysmal supraventricular tachycardia (PSVT), which is a type of arrhythmia that affects the heart’s upper chambers.
Milestone Pharmaceuticals Inc. has conducted several clinical trials to investigate etripamil's efficacy and safety. These studies have demonstrated that etripamil can rapidly terminate PSVT and help prevent its recurrence. In addition, etripamil has been found to be safe, well-tolerated, and effective in patients with normal cardiac function.
In addition to etripamil, Milestone Pharmaceuticals Inc. is also working on developing other drug candidates for the treatment of cardiovascular and metabolic disorders. The company's pipeline includes medications targeting hypertension, atrial fibrillation, and heart failure.
Milestone Pharmaceuticals Inc. has received substantial funding from a number of sources, including venture capital firms, strategic partners, and government grants. The company has also received orphan drug designation from the United States Food and Drug Administration (FDA) for etripamil, which provides incentives for the development of drugs that treat rare diseases.
Overall, Milestone Pharmaceuticals Inc. is a highly innovative biopharmaceutical company that is dedicated to developing novel therapies for the treatment of cardiovascular and metabolic disorders. The company's focus on developing targeted therapies that address unmet medical needs, combined with its robust clinical development program, positions it as a leader in this field.
Milestone Pharmaceuticals Inc. is primarily focused on developing drugs that target cardiovascular and metabolic disorders, including hypertension, atrial fibrillation, and heart failure. The company's lead product candidate is called etripamil, which is a calcium channel blocker that is delivered through a nasal spray. Etripamil is being developed for the treatment of paroxysmal supraventricular tachycardia (PSVT), which is a type of arrhythmia that affects the heart’s upper chambers.
Milestone Pharmaceuticals Inc. has conducted several clinical trials to investigate etripamil's efficacy and safety. These studies have demonstrated that etripamil can rapidly terminate PSVT and help prevent its recurrence. In addition, etripamil has been found to be safe, well-tolerated, and effective in patients with normal cardiac function.
In addition to etripamil, Milestone Pharmaceuticals Inc. is also working on developing other drug candidates for the treatment of cardiovascular and metabolic disorders. The company's pipeline includes medications targeting hypertension, atrial fibrillation, and heart failure.
Milestone Pharmaceuticals Inc. has received substantial funding from a number of sources, including venture capital firms, strategic partners, and government grants. The company has also received orphan drug designation from the United States Food and Drug Administration (FDA) for etripamil, which provides incentives for the development of drugs that treat rare diseases.
Overall, Milestone Pharmaceuticals Inc. is a highly innovative biopharmaceutical company that is dedicated to developing novel therapies for the treatment of cardiovascular and metabolic disorders. The company's focus on developing targeted therapies that address unmet medical needs, combined with its robust clinical development program, positions it as a leader in this field.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company that concentrates its efforts on developing and commercializing innovative therapies for cardiovascular diseases, with a significant emphasis on migraine headaches and induced hypertension. These conditions are major health challenges that affect a large population globally, and Milestone aims to address the treatment gap through its cutting-edge pharmaceutical products.
Segments of Focus
1. Cardiovascular Diseases: This segment represents Milestones commitment to treating conditions such as paroxysmal supraventricular tachycardia (PSVT), which is characterized by episodes of rapid heart rate. The company is focused on developing treatments that can provide immediate relief from symptoms associated with these cardiovascular episodes.
2. Migraine Management: Milestone is also addressing the growing need for effective migraine treatments. Given the debilitating nature of migraines and the limitations of current options, Milestones research and development in this area seeks to offer a new, effective solution for those affected by chronic migraines.
Products and Services
1. Etripamil
The cornerstone of Milestone Pharmaceuticals product portfolio is Etripamil, a novel therapeutic candidate that operates as an intranasal calcium channel blocker. It is primarily designed for:
- Treatment of PSVT: Etripamil is formulated as an intranasal spray that delivers rapid action to halt heart palpitations and restore normal heart rhythm within minutes. The therapeutic has advanced through clinical trials, demonstrating significant efficacy and safety profiles, making it a vital option for adults experiencing acute episodes of PSVT.
- Potential for Migraine Management: Milestone is exploring the use of Etripamil in a nasal spray formulation specifically aimed at migraine relief. In early-phase clinical trials, Etripamil has shown potential for providing quick and sustained relief from migraine attacks, marking a promising advancement in migraine therapies.
Intravenous (IV) Formulation of Etripamil
Recognizing that not all patients can utilize an intranasal delivery route, Milestone Pharmaceuticals has developed an intravenous formulation of Etripamil. Currently in Phase 2 clinical trials, this version is aimed at:
- Providing Alternative Administration: The IV formulation is designed for use in clinical settings where rapid administration is critical. It seeks to offer an effective alternative for individuals who may struggle with nasal delivery methods. Early data suggests that the intravenous formulation similarly helps to restore heart rhythm effectively.
Research and Development Focus
Milestone Pharmaceuticals is adamant about advancing the science behind cardiovascular and migraine therapies. The company is committed to:
- Innovation in Drug Delivery: Emphasizing the importance of patient-friendly delivery systems, Milestone is dedicated to refining the drug administration techniques that can ensure rapid onset of action, which is particularly crucial in emergencies related to PSVT or severe migraine attacks.
- Addressing Unmet Medical Needs: Milestones research initiatives are driven by the understanding that current treatments for conditions like migraine and PSVT have limitations. The focus on developing Etripamil and its formulations reflects the company’s commitment to fulfilling significant unmet medical needs within these therapeutic areas.
Conclusion
In conclusion, Milestone Pharmaceuticals Inc. stands at the forefront of biopharmaceutical innovation with a strong focus on cardiovascular diseases and migraine management. Through its lead candidate, Etripamil, and the exploration of both intranasal and intravenous formulations, the company is poised to make a substantial impact on the lives of millions worldwide by providing effective and timely therapeutic options for these critical health conditions. The ongoing research, coupled with development efforts tailored to meet patient needs, underlines Milestones ambition to reshape the treatment landscape for PSVT and migraines.
Segments of Focus
1. Cardiovascular Diseases: This segment represents Milestones commitment to treating conditions such as paroxysmal supraventricular tachycardia (PSVT), which is characterized by episodes of rapid heart rate. The company is focused on developing treatments that can provide immediate relief from symptoms associated with these cardiovascular episodes.
2. Migraine Management: Milestone is also addressing the growing need for effective migraine treatments. Given the debilitating nature of migraines and the limitations of current options, Milestones research and development in this area seeks to offer a new, effective solution for those affected by chronic migraines.
Products and Services
1. Etripamil
The cornerstone of Milestone Pharmaceuticals product portfolio is Etripamil, a novel therapeutic candidate that operates as an intranasal calcium channel blocker. It is primarily designed for:
- Treatment of PSVT: Etripamil is formulated as an intranasal spray that delivers rapid action to halt heart palpitations and restore normal heart rhythm within minutes. The therapeutic has advanced through clinical trials, demonstrating significant efficacy and safety profiles, making it a vital option for adults experiencing acute episodes of PSVT.
- Potential for Migraine Management: Milestone is exploring the use of Etripamil in a nasal spray formulation specifically aimed at migraine relief. In early-phase clinical trials, Etripamil has shown potential for providing quick and sustained relief from migraine attacks, marking a promising advancement in migraine therapies.
Intravenous (IV) Formulation of Etripamil
Recognizing that not all patients can utilize an intranasal delivery route, Milestone Pharmaceuticals has developed an intravenous formulation of Etripamil. Currently in Phase 2 clinical trials, this version is aimed at:
- Providing Alternative Administration: The IV formulation is designed for use in clinical settings where rapid administration is critical. It seeks to offer an effective alternative for individuals who may struggle with nasal delivery methods. Early data suggests that the intravenous formulation similarly helps to restore heart rhythm effectively.
Research and Development Focus
Milestone Pharmaceuticals is adamant about advancing the science behind cardiovascular and migraine therapies. The company is committed to:
- Innovation in Drug Delivery: Emphasizing the importance of patient-friendly delivery systems, Milestone is dedicated to refining the drug administration techniques that can ensure rapid onset of action, which is particularly crucial in emergencies related to PSVT or severe migraine attacks.
- Addressing Unmet Medical Needs: Milestones research initiatives are driven by the understanding that current treatments for conditions like migraine and PSVT have limitations. The focus on developing Etripamil and its formulations reflects the company’s commitment to fulfilling significant unmet medical needs within these therapeutic areas.
Conclusion
In conclusion, Milestone Pharmaceuticals Inc. stands at the forefront of biopharmaceutical innovation with a strong focus on cardiovascular diseases and migraine management. Through its lead candidate, Etripamil, and the exploration of both intranasal and intravenous formulations, the company is poised to make a substantial impact on the lives of millions worldwide by providing effective and timely therapeutic options for these critical health conditions. The ongoing research, coupled with development efforts tailored to meet patient needs, underlines Milestones ambition to reshape the treatment landscape for PSVT and migraines.